This guide covers everything Australian researchers need to know about Retatrutide — the most advanced GLP-1 class research compound available.
Retatrutide is a triple agonist activating GLP-1, GIP and glucagon receptors simultaneously. This mechanism sets it apart from single or dual-agonist compounds.
GLP1 Peptides Australia stocks Retatrutide in multiple formats including 5mg, 10mg, 20mg and 40mg vials, plus the convenient Synedica 40mg pen format. All orders ship Australia-wide with PayID and Bank Transfer accepted.